Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are incretin mimetics that both stimulate glucose-dependent insulin release and suppress glucagon secretion, leading to reduced blood glucose levels without affecting defence mechanisms to hypoglycaemia. This evidence concerns the gene GLP1R and Hypoglycemia.